Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ADCendo

Request full access

A Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers

Copenhagen, DenmarkFounded 2017Biotech & Life Sciences

About ADCendo

Adcendo is a biotechnology startup that specializes in the development of antibody-drug conjugates (ADCs), a type of cancer treatment that targets specific cancer cells. The company was founded in 2017 as a spin-off from the University of Copenhagen and Rigshospitalet. Its founders, Niels Behrendt, Lars Engelholm, and Christoffer Nielsen, have over 20 years of experience in cancer research and drug development.

Adcendo's primary focus is on the uPARAP receptor, a molecule involved in cancer development and metastasis. The founders have demonstrated that ADCs targeting this receptor can effectively treat cancer in preclinical models. This discovery led to the creation of Adcendo, which aims to further investigate and develop these findings into viable cancer treatments.

The company operates in the biotechnology and pharmaceutical market, serving clients such as hospitals, healthcare providers, and potentially, cancer patients. Its business model revolves around the research, development, and commercialization of its ADCs. Revenue is generated through the successful development and sale of these cancer treatments, as well as through partnerships with other biotech and pharmaceutical companies.

In 2021, Adcendo secured 51 million EUR in a series A investment round, which was extended by an additional 31 million EUR in 2023. This funding, provided by an international syndicate of life science and biotech investors, will support the company's ongoing research and development efforts.

Source: Dealroom company data

At a glance

Status
Operational
Employees
63
Open positions
None listed
Dealroom signal
67.5/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, Nordic Rising Star 2022, Top 50 Nordic Rising Star 2022 Denmark, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Apr 2026 $70M $712M TPG · Bpifrance · Ysios Capital · Venrock ↗
SERIES BOther financing Nov 2024 $142M $570M Ysios Capital · HealthCap · Gilde Healthcare · OrbiMed ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearEBITDAMargin
2026 —
2025 —
2024 —
2023 —
2022 —
2021 —
2020 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

ADCendo website traffic

Latest recorded traffic for ADCendo is 3.6K monthly website visits, up 89.5% over the last three months. ADCendo's team declined 4.5% over the past year.

Latest monthly visits3.6K 3-month web change+89.5% 1-year team growth-4.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

ADCendo in the Copenhagen ecosystem

Live from Dealroom

The ADCendo office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

21 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Novo Nordisk Foundation

Series A14 investors entered at this stage

Series B and later4 investors entered at this stage

  • Jeito Capital
  • Bpifrance
  • Vida Ventures
  • Export and Investment Fund of Denmark

Other known investors2 additional known investors

  • Rigshospitalet
  • University of Copenhagen
Team profiled 17 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See ADCendo’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.